Literature DB >> 6746751

Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells.

J J Castellot, D L Beeler, R D Rosenberg, M J Karnovsky.   

Abstract

Previous work from our laboratory has demonstrated that both anticoagulant and nonanticoagulant heparin species can inhibit the proliferation of vascular smooth muscle cells in vivo and in vitro. In this communication, we report studies on the structure-function relationships of heparin to its antiproliferative effect on vascular smooth muscle cells. These structure-function studies were carried out by preparing discrete sizes of heparin fragments and by chemically modifying heparin. The compounds were tested for their ability to inhibit rat and calf aortic smooth muscle cell growth. The minimum fragment size which retains some growth inhibitory activity is a hexasaccharide; maximal antiproliferative activity was obtained with dodecasaccharide and larger fragments. Both O-sulfation and N-substitution were found to be important for the growth inhibitory effect. Comparison of the antiproliferative and anticoagulant activities of the different heparin species has allowed us to identify several heparin molecules which have lost their anticoagulant properties, but retain antiproliferative activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746751     DOI: 10.1002/jcp.1041200309

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  24 in total

1.  Heparin stimulates elastogenesis: application to silk-based vascular grafts.

Authors:  Cassandra Saitow; David L Kaplan; John J Castellot
Journal:  Matrix Biol       Date:  2011-05-11       Impact factor: 11.583

2.  N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation.

Authors:  M L Purkerson; D M Tollefsen; S Klahr
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

3.  Heparin inhibits Ca2+/calmodulin-dependent kinase II activation and c-fos induction in mesangial cells.

Authors:  T Miralem; D M Templeton
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

4.  Heparin-treated, v-myc-transformed chicken heart mesenchymal cells assume a normal morphology but are hypersensitive to epidermal growth factor (EGF) and brain fibroblast growth factor (bFGF); cells transformed by the v-Ha-ras oncogene are refractory to EGF and bFGF but are hypersensitive to insulin-like growth factors.

Authors:  S D Balk; T M Riley; H S Gunther; A Morisi
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

5.  In vitro stimulation of human endothelial cells by derivatized dextrans.

Authors:  D Letourneur; J Champion; F Slaoui; J Jozefonvicz
Journal:  In Vitro Cell Dev Biol       Date:  1993-01

6.  Human smooth muscle cells of the aorta and vena cava: different sensitivity to the inhibition of proliferation by heparin in vitro.

Authors:  D G Thilo-Körner; R H Bödeker
Journal:  Klin Wochenschr       Date:  1985-08-01

7.  Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans.

Authors:  S A Kilfeather; S Tagoe; A C Perez; K Okona-Mensa; R Matin; C P Page
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 8.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

9.  Heparin and dibutyryl cAMP modulate gene expression in stimulated human saphenous vein smooth muscle cells.

Authors:  M Yamaguchi; S Diamond; H Watanabe; H Gallati; W Baur; J B Sharefkin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

10.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury.

Authors:  E R Edelman; D H Adams; M J Karnovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.